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Targeting Tumor-Associated Macrophages and 
Inhibition of MCP-1 Reduce Angiogenesis and Tumor 
Growth in a Human Melanoma Xenograft
Silvina Gazzaniga1, Alicia I Bravo2, Angelo Guglielmotti3, Nico van Rooijen4, Fabricio Maschi5, 
Annunciata Vecchi6, Alberto Mantovani6, José Mordoh7 and Rosa Wainstok1
Chemokines such as monocyte chemoattractant protein (MCP)-1 are key agonists that attract macrophages to 
tumors. In melanoma, it has been previously shown that variable levels of MCP-1/CCL2 appear to correlate with 
infiltrating macrophages and tumor fate, with low to intermediate levels of the chemokine contributing to 
melanoma development. To work under such conditions, a poorly tumorigenic human melanoma cell line was 
transfected with an expression vector encoding MCP-1. We found that M2 macrophages are associated to MCP- 
1+ tumors, triggering a profuse vascular network. To target the protumoral macrophages recruitment and 
reverting tumor growth promotion, clodronate-laden liposomes (Clod-Lip) or bindarit were administered to 
melanoma-bearing mice. Macrophage depletion after Clod-Lip treatment induced development of smaller 
tumors than in untreated mice. Immunohistochemical analysis with an anti-CD31 antibody revealed scarce 
vascular structures mainly characterized by narrow vascular lights. Pharmacological inhibition of MCP-1 with 
bindarit also reduced tumor growth and macrophage recruitment, rendering necrotic tumor masses. We 
suggest that bindarit or Clod-Lip abrogates protumoral-associated macrophages in human melanoma 
xenografts and could be considered as complementary approaches to antiangiogenic therapy.
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INTRODUCTION
Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a 
critical role in the recruitment and activation of macrophages 
during acute inflammation (Mantovani et al., 2004). It has 
also been shown that, in melanoma cell lines transduced with 
MCP-1 gene that secrete different levels of the chemokine, 
MCP-1 action is biphasic. Whereas high levels promote 
tumor rejection, low or intermediate levels support tumor 
growth (Nesbit et al., 2001). Macrophages are important 
components of the innate immunity against tumors, which 
are attracted by locally secreted chemokines (Brigati et al., 
2002; Coussens and Werb, 2002). Owing to their plasticity, 
the macrophage functional program appears to be defined by 
the presence of growth factors in the tumor microenviron-
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ment as well as by intercellular interactions (Mills et al.,
2000) . Consequently, there is a duality in the functional value 
of tumor-associated macrophages. When totally polarized to 
M1, macrophages are involved in type I reactions and may 
kill tumor cells. On the other hand, M2 macrophages tune up 
inflammation, produce angiogenic factors and metallopro­
teases, induce a certain degree of immunosuppression, and 
stimulate tumor growth (Mills, 2001; Brigati et al., 2002; 
Mantovani et al., 2002).
Human melanoma is a disease with extremely variable 
growth rates in vivo and on the basis of the above-mentioned 
results it seemed worth investigating (a) the type of 
macrophages that arrive to the tumor, (b) how to modulate 
macrophage infiltration, and (c) how the expression level of 
MCP-1 could be inhibited to diminish tumor growth rate.
To approach these issues, we have used the human 
melanoma cell line IIB-MEL-J as a model (Gazzaniga et al.,
2001) , which has no production of MCP-1 (Gazzaniga etal., 
unpublished results) and which grows slowly when 
xenografted into nude mice. We have transfected this cell 
line with an MCP-1-expression vector and obtained 
an intermediate MCP-1 producer, which grows faster 
in vivo. Bindarit (2-methyl-2-((1 -(phenylmethyl)-l H-indazol- 
3yl) methoxy) propanoic acid) inhibits MCP-1 production 
in vitro and in vivo (Guglielmotti et al., 2002) and the anti- 
MCP-1 action results in beneficial effects in models of some 
diseases (Guglielmotti etal., 2002; Bathia etal., 2005). This 
suggests that the blockage of this chemokine production or its 
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action is a major target for pharmacological intervention in 
different human diseases, raising the possibility of therapeutic 
strategies to target specific macrophages attracted by the 
chemokine MCP-1 at the tumor site. Clodronate (dichlor­
omethylene—biphosphonate) encapsulated into liposomes can 
be delivered so that it is captured by phagocytic cells. Killing 
of these cells is the result of intracellular accumulation and 
irreversible metabolic damage that causes apoptotic death 
(van Rooijen et al., 1996). Here, we provide direct evidence 
that M2 macrophages are present locally in MCP-1-produ­
cing melanoma, promoting vascularization and tumor 
growth. Most importantly, targeting macrophages or MCP-1 
production through two different pharmacological ap­
proaches renders tumors less aggressive with a clear 
reduction of intratumoral vascular network.
RESULTS
Transfection of the human IIB-MEL-J melanoma cell line
To establish a stable model to evaluate the contribution of 
MCP-1 to tumor growth, we have chosen the melanoma cell 
line IIB-MEL-J, which does not produce the chemokine. The 
level of MCP-1 released to the cell culture supernatant was 
less than 12pg/ml/106 cells/48 hours. After lipofection with 
the pLXSN-MCP-1 plasmid, we were able to select a stable 
subline, IIB-MEL-J-MCP-1, which expressed MCP-1 mRNA 
and released 940pg/ml/106 cells/48hours. Mock-transfected 
cells (with the empty vector pLXSN) retained the character­
istics of the parental line in terms of MCP-1 production 
(Figure 1a). Every experiment conducted thereafter, included 
parental and mock-transfected IIB-MEL-J as independent 
groups and will be referred as control lines along the work.
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Figure 1. Characterization of IIB-MEL-MCP-1-transfected cell line, (a) Expression of MCP-1 mRNA by melanoma cell lines. The amplified specific fragment of 
235 bp is present in the permanently transfected IIB-MEL-J-MCP-1. Analysis of /?-actin served as internal control, (b) Chemoattractant capacity of serum-free 
conditioned media from the different melanoma lines assayed in a chemotaxis chamber. The number of migrated macrophages after 2 hours was counted in five 
high-power fields. Determinations were done by triplicate (***P<0.0001, Student's t-test). (c) Tumor dimensions were measured with a caliper and for 
microscopic tumor masses, dimensions were taken on hematoxylin-eosin sections with reticulated ocular in 5-10 different tumor samples. Triangle: IIB-MEL-J- 
MCP-1 , square: IIB-MEL-J and mock-transfected lines. (*P= 0.015, Wilcoxon's rank-sum test), (d) In vitro growth rate: 50,000 cells of each line were plated onto 
96-well dishes and cultured in complete melanoma medium. Cells were quantified at different time points with 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide. Full square: parental line; full triangle: IIB-MEL-J-MCP-1; empty square: mock-transfected line. Determinations were done by 
quadruplicates. CCR2 expression in (e) control, (f) IIB-MEL-J-MCP-1, and (g) 1 G11 lines. Gray histogram corresponds to isotype control and white histogram to 
the reactivity to CCR2 chemokine receptor with rabbit mAb. Percentages depicted above the marker line indicate the fraction of CCR2-positive cells.
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To test whether the chemokine released by IIB-MEL-J- 
MCP-1 was functional, serum-free culture supernatants were 
seeded in the lower compartment of a chemotaxis chamber. 
Monocyte/macrophage migration was only induced by IIB- 
MEL-J-MCP-1-conditioned medium (Figure 1b) and blocked 
when supernatants were preincubated with a specific anti­
body against MCP-1 (data not shown). Control lines-condi- 
tioned media were not chemoattractant for monocytes/ 
macrophages (Figure 1b). When injected subcutaneously 
into nude mice, IIB-MEL-J-MCP-1 developed larger tumors 
than those of control cell lines: tumors attained statistical 
significant differences (P= 0.015) after 11 days of inoculation 
up to the end of the observation period (day 20) (Figure 1c). 
This increased growth velocity could not be attributed to an 
alteration of cell properties after transfection. In vitro growth 
kinetics of IIB-MEL-J-MCP-1 and control cell lines were 
similar (Figure 1 d). In addition, the main receptor for MCP-1, 
CCR2, was absent (Figure 1e and f) discarding a putative 
autocrine role in tumor growth rate.
Inflammatory infiltration and angiogenesis
Tumor samples were obtained at different intervals to 
examine the occurrence and localization of inflammatory 
infiltrate. Recruitment of macrophage-like cells within and 
around tumors was significantly higher (P=0.01) in MCP-1- 
transfected tumors than in control tumors from early stages of 
tumor establishment until the end of the observation period 
(Figure 2a and b and Table 1). Eleven days after IIB-MEL-J- 
MCP-1 injection, the macrophage-like cells recruitment 
persisted and was accompanied by fibroblasts and edema, 
alterations that were absent in control tumors (data not 
shown). There was scarce presence of péritumoral lympho- 
cyte-like cells, although polymorphonuclear neutrophils 
increased peritumorally 4 days post-IIB-MEL-J-MCP-1 cells 
implantation (Table 1). The above-described inflammatory 
infiltrate was absent in control tumors.
To analyze the phenotypic identity of the mononuclear 
infiltrates and the degree of vascularization, consecutive tumor 
sections were stained with primary antibodies to detect CD31, 
F4/80, and CX3CR1 expression. Four days after IIB-MEL-J- 
MCP-1 injection, a peripheral border of incipient vessels 
appeared as well as isolated CD31 + cell clusters (Figure 2c). 
Concerning F4/80, a striking positivity was found around 
tumor mass and also among neoplastic cells (Figure 2e). For 
CX3CRI, a fainter staining was present peri-and intratumorally 
partially overlapping with F4/80 areas (data not shown).
Figure 2. Inflammatory infiltration and angiogenesis, (a) Mononuclear cells are mainly present among IIB-MEL-J-MCP-1 cells (11 days growing tumors)
(b) Control tumors present no mononuclear infiltration. Bar= 10^m. Immunohistochemical analysis identifying (c and d) CD31 + and (eand f) F4/80 + cells in 
11-day (c and e) IIB-MEL-J-MCP-1 (d and f) and control melanoma. Bar= 125 ¿zm.
www.jidonline.org 2033
S Gazzaniga et al.
Targeting TAM Inhibits Angiogenesis and Tumor Growth
Macrophage-like cells Lymphocyte-like cells Polymorphonuclear cells
Table 1. Quantitative analysis of péritumoral and intratumoral infiltrating cells1
Péritumoral
Days Control MCP-1 + Control MCP-1 + Control MCP-1 +
4 2 (0-11 ) 4** (0-26) 0 (0-4) 0 (0-3) 0 (0-3) 2** (0-22)
11 1 (0-4) 4** (0-14) 0 0 0 (0-2) 0 (0-2)
20 2 (0-20) 33** (0-70) 0 (0-2)
Intratumoral
0 (0-2) 0 (0-3) 0 (0-6)
4 2 (0-10) 5** (0-33) 0 (0-2) 0 (0-2) 0 (0-3) 0 (0-8)
11 2 (0-6) 3* (0-9) 0 0 0 (0-1 ) 0
20 0 (0-2) 8** (0-30) 0 (0-1 ) 0 (0-1 ) 0 (0-1 ) 0
MCP, monocyte chemoattractant protein.
^Counts were performed in 10 fields of original magnification x 1000. Values correspond to medians and ranks. *P=0.05 and **P=0.01 (Wilcoxon's rank 
test).
Table 2. Immunoreactive cells in 11-day tumors1
Vessels CD31 + clusters F4/80+ cells CX3CR1+ cells
IIB-MEL-J-MCP-1 Intratumorally +++ +++ 140 35
Peritumorally +++ +++ 242 37
Control Intratumorally - - 2 0
Peritumorally +++ +++ 174 42
’Total cell counts performed at 10 high-power fields and vascularization at original magnification x 200 fields. Vascular structures and cell clusters were 
ranked as: + (<10 elements); ++ (10-20 elements), and +++ (>20 elements).
When 11-day IIB-MEL-J-MCP-1 tumors were analyzed, a 
strong positivity for CD31 was detected and revealed a 
massive branched intratumoral vascular network. This 
important vascularization was completely absent in control 
tumors where MCP-1 was not produced. Surprisingly, no 
differences were found peritumorally in terms of CD31 + 
vessels and cell clusters (Table 2). The intratumoral differ­
ences between IIB-MEL-J-MCP-1 and control tumors were 
also extensive to F4/80 and CX3CR1 macrophages infiltration. 
Surrounding macrophages were present in control tumors, 
although recruitment was increased in those generated from 
cells transfected for MCP-1 expression (Table 2). Eleven days 
post-injection of neoplastic cells, tumors showed a well- 
established angiogenic network. Consequently, we focused 
on days 4 and 11 as a prevascularized and vascularized time 
points in tumor development, respectively.
The immunohistochemical analysis revealed the presence 
of cells identified as macrophages but this marker positivity 
does not reveal their functional significance in tumor tissues. 
For this purpose, two characteristic enzymes were deter­
mined. Type I macrophages (M1 macrophages), which 
synthesize inducible nitric oxide (¡NOS) but not arginase, 
were proposed to be tumoricidal macrophages, whereas M2 
macrophages, which synthesize arginase but not iNOS, 
would be protumoral (Sironi et al., 1999; Schmeisser et al., 
2001; Koide et al., 2004).
To determine which type of infiltrating macrophages are 
present at IIB-MEL-J-MCP-1 melanomas, extracts from 4-day 
tumor sites were prepared to test in vitro arginase and iNOS 
activities (Figure 3). Macrophages infiltrating IIB-MEL-J-MCP- 
1 tumors presented a significant reduction of nitric oxide 
(P= 0.005) and arginase tended to be augmented with 
respect to control tumor sites, although this difference does 
not reach statistical signification (Figure 3).
Depletion of macrophages with Clod-Lip
To determine how critical macrophages were to the 
increased growth ability of MCP-1-transfected melanoma, 
mice were depleted of phagocytic cells by the administration 
of Clod-Lip as described. Intravenous and local injections of 
Clod-Lip were intended to eliminate early recruitment of 
macrophages, which could be attracted by the chemokine 
released once transfected tumor cells were injected. Under 
this condition, IIB-MEL-J-MCP-1 tumors grown in mice 
treated with Clod-Lip showed a reduction superior to 70% 
(P= 0.0003, Student's t-test) in tumor bulk (Figure 4a) as 
compared with tumor growth in undepleted mice. Mice 
survival also increased with macrophage depletion (data not 
shown). Growth rates for parental or mock-transfected tumors 
remained unchanged with treatment (Figure 4b).
To verify the intensity of macrophage depletion obtained 
by Clod-Lip, tumor sites from Clod-Lip-treated and untreated
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Figure 3. Infiltrating macrophages profile. Four-day tumor sites or normal 
tissue were processed and analyzed for arginase content as a measure of urea 
production and nitric oxide. Results were expressed as mean + SD.
(*P= 0.005, Student's t-test).
mice could not be stained with F4/80 owing to intense 
necrosis and chromogen deposition. Instead, a fluorochrome- 
labelled CD11b mAb was used. Abundant positive macro­
phages were easily identified at the tumor site in 4-day IIB- 
MEL-J-MCP-1 but were scarcely present in Clod-Lip-treated 
tumor (Figure 4c). To investigate whether macrophage 
depletion had an impact on vascularization, tumor biopsies 
were analyzed for CD31 expression (Figure 4d). A deep 
reduction in angiogenesis was observed with respect to 
nontreated tumors. Tumor vessel circumferences were 
significantly reduced (64.57 + 5.86 vs 128.12 + 9.13 /rm; 
P= 0.003) (Figure 4d inset and 4e). In contrast, control 
tumors did not present variations of vessels morphology with 
treatment (not shown). To discard a direct cytostatic/cytotoxic 
effect of Clod-Lip on melanoma cells or endothelium, cells 
were incubated in vitro with Clod-Lip or phosphate-buffered- 
saline-Lip. No significant effect on viability was recorded 
neither on different tumor nor endothelial cells (ECs) by Clod- 
Eip exposure during 30 (Figure 4f) or 72 hours (not shown), 
whereas this treatment was cytotoxic for macrophages and 
polymorphonuclear cells (P=0.05, Figure 4f).
Bindarit treatment
Even when an important reduction in tumor burden was 
obtained with Clod-Lip as a consequence of disrupting 
macrophages recruitment to tumor site, there was an 
incipient angiogenesis characterized by smaller vessels. This 
precarious microvascular development could be because of 
some angiogenic potency of MCP-1 itself. To address this 
issue, mice were injected intraperitoneally with bindarit at a 
dose of 100mg/kg twice a day, beginning the same day that 
tumor cells were subcutaneously inoculated. Bindarit treat­
ment was maintained until the animals were killed to sample 
tumor tissues for histology. The analysis revealed a reduction 
in IIB-MEE-J-MCP-1 tumor volume with respect to control 
tumors, both at days 4 and 11 post-treatment (P=0.05, 
Wilcoxon's rank test) (Figure 5a). Exclusively, tumors expres­
sing MCP-1 were almost completely necrotic when 
examined at days 4 and 11 after treatment (P= 0.0022 and 
0.01) (Figure 5b and c). The combination of bindarit and 
Clod-Lip did not improve this result (data not shown). 
Macrophages recruitment was abolished by bindarit (Figure 
5c). Control lines were not affected by the drug (data not 
shown). Bindarit, even at the maximal concentration, did 
not exhibit a direct in vitro cytotoxic effect on melanoma 
(Figure 6a and b) or ECs (Figure 6c), although it inhibited 
MCP-1 expression (Figure 6d).
Effect of MCP-1 on ECs
The results obtained above suggest that MCP-1 plays a role to 
vascularize IIB-MEE-J-MCP-1 tumors, as there is still a 
precarious neovessel development even after reducing 
macrophages with Clod-Lip. To assess whether MCP-1 could 
induce vascularization, murine microvascular ECs were 
incubated with different concentrations of recombinant 
MCP-1. No induction of proliferation was found (Figure 7a), 
discarding its contribution as a mitogenic agent on ECs. 
However, when the same microvascular ECs were incubated 
in matrigel, tubular structures were induced to organize in the 
presence of recombinant chemokine (100ng/ml) (Figure 7b) 
or conditioned supernatants from IIB-MEL-J-MCP-1 (data not 
shown). A specific antibody against MCP-1 aborted ECs 
organization in tubules and only precarious buds were 
observed emerging from cell clusters (Figure 7c). Tubule 
structures were not altered by the addition of an isotype 
control antibody and no structures were formed when 
microvascular ECs were grown alone or after adding 
conditioned supernatants from control lines (not shown).
DISCUSSION
MCP-1 released by cancer cells recruits macrophages into 
tumor tissue (Desbaillets et al., 1994; Negus et al., 1997; 
Valkovic et al., 1998). The role of this chemokine in tumor 
progression and metastasis is a subject of interest in prognosis 
as well as in the development of possible antitumor strategies 
(Varney et al, 2002; Ohta et al., 2003; Koide et al., 2004; 
Colombo and Mantovani, 2005; Kuroda et al., 2005).
Macrophages respond to the released chemotactic envir­
onmental signals with diverse functional programs (Mills 
et al., 2000) and this inflammatory scenario has been 
associated with neoplasia (Coussens and Werb, 2002; 
Balkwill et al., 2005).
In this study, we performed transfection of the human 
melanoma cell line IIB-MEL-J (negative for MCP-1 produc­
tion) with the purpose to have a MCP-1 intermediate­
producer melanoma model to distinctively analyze the 
contribution of this chemokine in the profile of recruited 
macrophages and the effect on tumor growth. The compari­
son of different melanoma cell lines with spontaneous
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Figure 4. Clod-Lip treatment. Tumor dimensions after macrophage depletion with Clod-Lip in (a) IIB-MEL-J-MCP-1 and (b) control tumors. The day before tumor 
cell injection, mice were injected with 200¿zl of clodronate liposomes intravenously and 50 ¿d subcutaneously in the region where tumor cells would be 
injected. Depletion was maintained by systemic administration of 200 ¿¿I Clod-Lip dose once per week, (c) Macrophage recruitment in 4-day IIB-MEL-J-MCP-1 
is highly diminished after Clod-Lip treatment. Cryostat tissue sections were incubated with CD11b-TRJTC. Bar= 100/^m. (d) Tumor angiogenesis in 
Clod-Lip mice. Tumor sections from IIB-MEL-J-MCP-1 tumor grown in Clod-Lip-treated and untreated mice were immunostained for CD31 detection. 
(Bar=100/^m, insets bars: 100/^m). (e) Quantification of tumor vessels areas was performed on immunostained sections with Kontron Electronics software 
coupled to an image analyzer, (f) In vitro Clod-Lip cytotoxicity: cells were incubated in the presence of Clod-Lip (gray bars) and phosphate buffered-saline-Lip 
(white bars) in 5% complete medium and exposed for 29 hours at 1.5 ¿¿I of Clod-Lip (9 ¿zg) or phosphate buffered-saline-Lip. Cell viability was assayed 
with 3-(4,5-di methyl th iazol-2-yl)-2,5-dipheny I tetrazo hum bromide and absorbances read at 595 nm. Values correspond to the mean of quadruplicates. Two 
independent experiments were performed. (*P<0.04, Students t-test).
capacity to produce MCP-1 could be confusing as there are 
several angiogenic and antiangiogenic factors that could not 
be kept as constants. Most importantly, in this work, we 
focused on the effect of Clod-Lip and bindarit as putative 
agents to abolish protumoral effect of macrophages.
At the light of our results, the significant presence of 
intratumoral macrophages during the early stages of tumor 
progression and their persistence during evolution seem to be 
responsible for tumor growth promotion. We found that 
tumor dimensions of IIB-MEL-J-MCP-1 tumors enhanced 3.5-
2036 J ournal of Investigative Dermatology (2007), Volume 127
S Gazzaniga et al.
Targeting TAM Inhibits Angiogenesis and Tumor Growth
a * b # **
140350 n
'Ç 300 • 120- •
ê 250 • e 100
<D
E 200 
| 150 — VI a o
80-
60- I
b 100-
| 50 - •
• -4-
8z 40
20 -
I
4 days 11 days 4 days 11 days
Bindarit - + - + Bindarit - + - +
C Vehicle-treated IIB-MEL-J-MCP-1 Bindarit-treated IIB-MEL-J-MCP-1
Figure 5. Bindarit treatment. Analysis of (a) tumor volume and (b) necrotic regions in IIB-MEL-J-MCP-1 tumor-bearing mice. Biopsies were obtained at
4 and 11 days after treatment, counterstained with hematoxylin-eosin, and dimensions measured with microscope caliper. *P=0.05, s/J=0.01, **P= 0.0022.
(c) Representative images of 11-day IIB-MEL-MCP-1 tumors. A tumor from vehicle-treated animals appeared surrounded by macrophage infiltration 
(arrowheads) and a tumor from bindarit-treated mice depicted profuse necrosis (n) and no macrophage infiltration at the periphery. Bar = 200 ¿an.
and 18-fold after 4 and 11 days, respectively. The absence of 
CCR2 expression in melanoma cells discards the possibility 
of autocrine effect of the chemokine released by IIB-MEL-J- 
MCP-1 cells.
Apart from F4/80-positive cells recruitment, an important 
afflux of CD31 + cells was present nearby the incipient 
tumors. We also found a strong reduction in the levels of 
nitric oxide in IIB-MEL-J-MCP-1 tumors and an augmented 
arginase activity, outlining the presence of M2 macrophages 
recruited to the tumor. We propose that IIB-MEL-J-MCP-1 
tumors grew highly vascularized owing to the presence of M2 
macrophages, which could be contributing with an important 
source of angiogenic factors (Schmeisser et al., 2001; 
Coussens and Werb, 2002; Varney et al., 2005) or favoring 
vasculogenesis (Anghelina et al., 2004; Anghelina et al., 
2006).
The protumoral effect of infiltrating macrophages in IIB- 
MEL-J-MCP-1 was confirmed by Clod-Lip treatment results. 
We observed a substantial reduction in tumor growth MCP-1- 
transfected melanoma xenografts after macrophage deple­
tion. We did not find direct cytotoxicity on melanoma cells 
or endothelial employing Clod-Lip, which implies that the 
drug is captured selectively by phagocytic cell and there 
is no uptake by the other two cell types in the tumor. 
Clodronate is a non-nitrogen biphosphonate and when 
encapsulated, it is metabolized intracellularly to a fi-y 
methylene analog of adenosine triphosphate, that is cytotoxic 
to macrophages in vitro (van Rooijen etal., 1996; Lehenkari 
et al., 2002). Without encapsulation, clodronate exerts no 
inhibition in cell proliferation either in vitro or in vivo in 
solid tumors (cutaneous and uveal melanomas) (Knight etal., 
2005).
Instead, nitrogen-containing biphosphonates had a direct 
effect through induction of apoptosis on tumor cells 
(Yamagishi etal., 2004; Knight etal., 2005).
Thus, the choice of Clod-Lip allowed dividing clearly the 
role of macrophages respect to a direct influence on tumor 
cells.
Even when there was a significant tumor reduction in 
IIB-MEL-J-MCP-1 with Clod-Lip treatment, we found that 
there was still perfusion through a poor vessel network 
with very small calipers. As it has been previously shown, 
the origin of this modest vascular formation could be 
owing to EC migration and/or sprouting from local residing 
ECs or recruitment of circulating endothelial progenitors 
(Asahara et al., 1997; Skovseth et al., 2002; Spring et al., 
2005).
By using bindarit, a molecule that has been shown to 
inhibit MCP-1 production both in vitro and in vivo (Sironi 
etal., 1999; Guglielmotti etal., 2002; Bathia etal., 2005), we
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Figure 6. Evaluation of bindarit cytotoxicity in vitro. Viability of (a) IIB-MEL- 
J-MCP-1 and control lines; (b) IIB-MEL-IAN and IIB-MEL-LES, and (c) EC lines 
were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay. Values correspond to the mean of quadruplicates. Two 
independent experiments were performed, (d) Immunodot detection of MCP- 
1 production in 48 hours-conditioned supernatants of the different melanoma 
cell lines cultured in absence or presence of bindarit (500/zm). Human 
recombinant MCP-1 (200 ng, Peprotech) was seeded as positive control and 
culture media as negative control.
could abolish such vascularization, rendering tumors almost 
completely necrotic. When necrosis was not complete, the 
scarce viable remaining tumor cells were exclusively located 
at the periphery of the tumor mass. As no direct cytotoxicity
appeared from in vitro assays, the effect of bindarit treatment 
was assumed to happen because of the lack of attracting 
signals for the macrophages.
It was observed, in a macrovascular endothelium model as 
human umbilical vein endothelial cells (Salcedo etal., 2000) 
and in this paper using microvascular ECs (Figure 7), that 
MCP-1 induces ECs to arrange spatially forming tube-like 
structures without evident proliferation (Figure 7). This 
behavior is MCP-1-specific provided that the tubularization 
process was blocked by a specific antibody to the chemokine 
but not by the appropriate isotype control. Consequently, 
according to our results, MCP-1 would be predisposing ECs to 
an "angiogenic state" but the signals to proliferate would 
come with the presence other angiogenic component/s of 
tumor microenvironment. Vascular Endothelial Growth 
Factor (VEGF) could be one of these candidates, as it is 
expressed by IIB-MEL-J melanoma cells and transfectants 
(data not shown). The monocyte is an example of a non-EC 
type that is positive for VEGF R1, active on monocyte 
chemotaxis (Mantovani et al., 2004). According to these 
evidences, it is tempting to speculate that, when only VEGF is 
present, melanoma vascularizes poorly, as it occurs with IIE>- 
MEL-J tumors. Contrarily, with MCP-1 adjuvancy, more 
macrophages reach the tumor site to trigger a profuse 
vascular network, permitting a more aggressive tumor 
development.
This role of MCP-1 in orchestrating recruitment of M2 
macrophages but, above all, tumor vascularization by multi­
ple ways drives the attention to future therapies using drugs 
like Clod-Lip or bindarit, which could block or reduce the 
inflammatory effects of this chemokine.
MATERIALS AND METHODS
Melanoma cell lines
The human melanoma cell lines IIB-MEL-J and transfectants, IIB- 
MEL-IAN and IIB-MEL-LES were maintained in DMEM: Ham F12 
medium (1:1), supplemented with 10% fetal bovine serum (FBS), 
20 nM sodium selenite, 100^m ascorbic acid, 0.15mg/ml sodium 
pyruvate, 0.3mg/ml galactose, 5 /zg/ml insulin, and 2 itim glutamine 
(melanoma medium) as previously reported (Gazzaniga etal., 2001). 
Cells were regularly tested to be mycoplasma-free. Transfection was 
performed with Lipofectamine™ (Life Technologies, Gaithersburg, 
MD) with the pLXSN vector bearing a 700-bp long fragment of 
human MCP-1 cDNA or with the empty vector (mock transfection). 
Cultures were then selected with 800^g/ml G418 (Life Technolo­
gies), cloned, and expanded as cell lines. For tumor generation, 
1.5 x 106 cells were subcutaneously injected in athymic male NIH 
(S)-nu mice (6-8 weeks old, obtained from the Faculty of Veterinary 
Sciences Facility, University of La Plata, Buenos Aires). Animal 
handling and care were conducted in conformity with national and 
international policies.
MCP-1 and CCR2 determinations
Released MCP-1 was quantified with commercially available 
antibodies for ELISA (BD Biosciences, NJ). Development was 
performed by adding chromogen substrate ABTS (KirKegaard and 
Perry, Gaithersburg, MD) and the plates were read at 405 nm in an 
automatic ELISA reader (BIORAD Laboratories Inc, Hercules, CA).
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Figure 7. Effect of MCP-1 on ECs. (a) Microvascular proliferation in response to variable concentrations of human recombinant MCP-1. Cells were grown on 
gelatin-coated wells in the presence of 0.5% FBS and after 24 hours cell number was revealed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
(b) Microvascular ECs depicting tube formation in vitro after cultured for 4 days in the presence of matrigel plus 100ng/ml of human MCP-1. (c) ECs aborted 
tubularization when grown in matrigel plus 100ng/ml of human MCP-1 plus MCP-1 antibody (1 /ig/ml). Bar = 10/im.
MCP-1 mRNA was determined by reverse transcriptase-PCR as 
described by Luciani et al. (1998) using extracted RNA from every 
cell line as template and the following specific primers (forward 5'- 
CTCAGCCAGATGCAATCAATG-3' and reverse 5'-GTTCAAGTCTTC 
GGACTTTGG-3').
CCR2 determination was performed by FACS analysis on 1% 
paraformaldehyde-fixed cells using rabbit anti-human CCR2 (Ab­
eam, Cambridge Science Park, Cambridge, UK) (1/25) and goat anti­
rabbit conjugated to FITC (Sigma Chemicals Co., St Louis, MO) 
(1/140). Results were analyzed with WinMDi program. Markers 
were set with an inclusion criteria of less than 5% of the isotype 
control population. The percentage of positive cells were calculated 
with the statistical function of WinMDi program.
Treatments
For macrophage depletion, a suspension of clodronate liposomes 
containing about 6mg clodronate per 1 ml suspension was 
employed. Clodronate was a gift of Roche Diagnostics (GmbH, 
Mannheim, Germany) and it was encapsulated in liposomes as 
described earlier (van Rooijen and Sanders, 1994). Other reagents 
for preparation of liposomes are: phosphatidylcholine (Lipoid, 
GmBH, Germany) and cholesterol (Sigma Chemicals Co.,). 
Clodronate liposomes (200 and 50/zl) were administered intrave­
nously (by retroorbital puncture) and subcutaneously (to deplete 
local draining areas) the day before tumor cells injection and 
thereafter every 5-7 days. For in vitro assays, 9^g/well were 
employed.
Bindarit (Angelini Farmaceutici, ACRAF SpA, Italy) was intraper­
itoneally administered twice daily at a dose of 100mg/kg weight 
(12.5 ml/kg body weight). The control group received vehicle (0.5% 
methylcellulose). Mice were killed at day 4 or 11 and tumors were 
fixed in 10% buffered formalin. Tumor sizes and necrosis were 
measured with a microscope caliper. Experiments (either with Clod- 
Lip treatment or bindarit) were repeated twice and 4-6 animals were 
included in each group. For in vitro assays, the compound was 
resuspended in melanoma culture medium supplemented with 5% 
FBS, added to cell cultures at 70-80% confluency, and incubated for 
48 hours. Cell viability was determined with 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium bromide and culture supernatants 
were evaluated for MCP-1 production.
Tissue processing
For every group, tumors were bisected: one half of each specimen 
was fixed in 10% buffered formalin, embedded in paraffin, sectioned 
at 4-7 fim, and stained with hematoxylin-eosin. The other half was 
frozen and stored at —80°C for immunohistochemistry. Briefly, 
acetone-fixed tumor sections were blocked with 5% normal rabbit 
serum and incubated with optimal dilutions of the primary 
antibodies. Rat anti-mouse mAbs used were MEC 13.3 (BD 
Biosciences, Pharmingen, San Diego, CA) for CD31 detection, F4/ 
80 (Serotec Ltd., Oxford UK) for macrophages and anti-CX3CR1 
fractalkine receptor (BD Biosciences). The specific binding was 
revealed using 1/100 goat anti-rat IgG (Sigma Chemicals Co.), 1/500 
rat peroxidase-antiperoxidase complex (Accurate Chemicals, West­
bury, NY), and 0.05% 3,3'-diaminobenzidine (Sigma Chemicals Co.) 
plus 0.03% H2O2. Endogenous peroxidase activity was blocked with 
0.3% H2O2. All reagents except primary antibodies were used as 
controls to confirm specific antibody binding.
www.jidonline.org 2039
S Gazzaniga et al.
Targeting TAM Inhibits Angiogenesis and Tumor Growth
Quantitative evaluations
Tumor bulk in vivo was reported as volume, determined by 
measurement of the smallest and largest dimensions of the tumors 
with a caliper. For microscopic tumors, dimensions were measured 
with a reticulated ocular on counterstained tissue samples by 
hematoxylin and eosin. Volumes were calculated as (axir)/2, 
where a is the larger dimension and b is the smaller dimension. 
Determination of vessels areas were performed with an image 
analyzer (KS 300 Kontron Electronik) coupled to an Axioplan 
microscope (Zeiss, Germany). Cells were counted in at least 10 
fields/sample at original magnification x 1000.
NO and arginase assay
NO released in the cultures was measured by Griess reaction as the 
amount of NO3 and NOT produced by using a nitrate/nitrite assay 
kit (Cayman Chemical, Ann Arbor, Ml). Arginase activity was 
measured in cell lysates as described by Corraliza et al. (1994).
EC viability
Ten thousand murine 1G11 ECs (Dong et al., 1997) and REC-A4 ECs 
(Gazzaniga et al., 2004) were plated on gelatin-coated wells, left 
overnight for adherence in DMEM medium supplemented with 0.5% 
FBS, 2 itim glutamine, 1% nonessential amino acids and 2 itim 
sodium pyruvate. H5V (Garlanda et al., 1994) were grown in DMEM 
medium supplemented with 2 itim glutamine and 0.5% FBS and 
plated without coating. Subsequently, cells from every cell line were 
incubated for 24 hours with different drugs (bindarit, Clod-Lip, or 
vehicles). After incubation, living cells were revealed by incubation 
with 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (Sigma Chemicals Co.) and absorbances read at 595 nm. 
Determinations were done by sextuplícate.
Tube-like structures in matrigel
Fifty thousand ECs (1G11) were plated on coverslips together with 
matrigel (BD) (1.5 mg/ml) diluted in rhMCP-1 (Peprotech, Rocky 
Hill, NJ), melanoma cells-conditioned medium. A mAb against 
MCP-1 antibody (BD) (1 /zg/ml) was used to block MCP-1. Plates 
were monitored everyday and photographs were taken at day 4 after 
fixation with 1% paraformaldehyde in phosphate-buffered solution.
Chemotaxis assay
Migration of cells was evaluated using 5-/im pore size filters (Neurop­
robe Inc, Gaithersburg, MD) placed in a Boyden chamber. Every 
melanoma line was grown till 90% confluence, maintenance medium 
was removed and left for 48 hours in melanoma medium 1% FBS. 
These conditioned media were placed into the lower chamber of the 
Boyden chamber. Murine macrophages obtained from peritoneal cavity 
were resuspended in serum-free melanoma medium at a concentration 
of 1.5 x 106cells/ml and 40p] of cell suspension was placed onto the 
upper chamber. A mAb against MCP-1 antibody (BD) (1 /zg/ml) was 
used to ensure specific migration. After an incubation of 2 hours at 37°C 
in 5% CO2, the upper chamber was removed and the cells in the lower 
face of the filter stained and counted in five fields (original 
magnification x 400). Determinations were done by triplicate.
Statistical analysis
In vitro data were analyzed by using Student's t-test and in vivo 
results with the nonparametric Wilcoxon's rank sum test using 
Statistix software version 8.0 (Analytical Software, Tallahassee, FL). 
P^0.05 was considered statistically significant.
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